west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "MUC1" 3 results
  • Optimization of HSP65-MUC1 Purification in Pilot Scale and Identification of Methods to Detect Biological Function

    ObjectiveTo optimize HSP65-MUC1 fusion protein purification in pilot scale through protein purification techniques and identify the methods for biological activity detection. MethodsE. coli expressing HSP65-MUC1 was obtained by fermentation, then homogenized to obtain the supernatant. To acquire high-purity, high-quality HSP65-MUC1, the supernatant was treated with saturated ammonium sulfate, phenyl sepharose FF column and Q FF ion-exchange chromatography column purification. The expression of CD86 on the surface of DC cells treated with HSP65-MUC1 was determined with flow cytometry. ResultsE. coli containing pET28a-HSP65-MUC1 recombinant plasmid can effectively express target protein. A total of 413.7 mg of HSP65-MUC1 was obtained after 10 g of fermented cells was treated with saturated ammonium sulfate, phenyl sepharose FF column and Q FF ion-exchange chromatography column, and the purity was nearly 96%. Compared with negative control (10.13%±0.89%), purified HSP65-MUC1 could significantly improve the expression of CD86 on the surface of DC cells (29.98%±1.02%). ConclusionThe pilot scale production of purified HSP65-MUC1 has been effectively optimized, and the methods of its biological activity detection have been identified, which simultaneously provides the basis for clinical studies.

    Release date: Export PDF Favorites Scan
  • Effect of MUC1 Over-expression on Chemotherapy of 5-Fluorouracil and Cisplatin for Esophageal Cancer Cells

    ObjectiveTo investigate MUC1 over-expression on chemotherapy of 5-fluorouracil and cisplatin for esophageal cancer cells. MethodsMUC1 over-expression and stable silencing of MUC1 expression esophageal cancer cell lines were constructed. Xenograft model of esophageal cancer was established in nude mice. Cisplatin (8 mg/kg, day 1 and day 7)and 5-fluorouracil (20 mg/kg, day 1 to 6)were injected intraperitoneally. Tumor volume and body weight of nude mice were measured. Tumor growth curve and body weight curve were drawn, and tumor inhibitory rate was calculated. ResultsBoth cisplatin and 5-fluorouracil suppressed tumor growth of MUC1 over-expression esophageal cancer nude mice. Body weight and tumor volume of nude mice of cisplatin and 5-fluorouracil groups were significantly smaller than those of the control group (P < 0.05), and the inhibitory effects of cisplatin were significantly greater than those of 5-fluorouracil (P < 0.05). There was no significant inhibitory effect in stable silencing of MUC1 expression esophageal cancer nude mice. ConclusionBoth cisplatin and paclitaxel can suppress the growth of MUC1 over-expression esophageal cancer, and cisplatin has greater inhibitory effects than 5-fluorouracil in tumor volume and body weight of nude mice.

    Release date: Export PDF Favorites Scan
  • 非小细胞肺癌隐匿性淋巴结转移的基因诊断

    目的 探讨非小细胞肺癌(NSCLC)隐匿性纵隔淋巴结转移病灶的基因诊断方法. 方法 应用逆转录聚合酶链反应法(RT-PCR), 检测30例NSCLC患者(实验组,N0,Ⅰa~Ⅱb期)手术后病理诊断为阴性的138枚纵隔淋巴结中MUC1基因mRNA的表达,并用30枚肺良性疾病的局部淋巴结作阴性对照(阴性对照组),用30枚经病理证实有转移的NSCLC纵隔淋巴结作阳性对照(阳性对照组).对患者进行随访,用χ2检验比较MUC1基因mRNA阳性者和阴性者的预后差别. 结果 阴性对照组30枚肺良性疾病的局部淋巴结均无MUC1基因mRNA表达(特异性为100%),阳性对照组30枚经病理证实有转移癌的肺癌纵隔淋巴结中26枚检测到MUC1基因mRNA的表达(敏感性为87%).实验组9例患者的11枚淋巴结中检测到MUC1基因mRNA表达(检出率8.0%),患者的分期上调为Ⅲa期.实验组中MUC1基因mRNA阳性患者预后不良,随访2年有4例复发、转移或死亡;MUC1基因mRNA阴性者仅1例转移(P<0.05 ). 结论 应用RT-PCR法检测纵隔淋巴结中MUC1基因mRNA的表达可以诊断肺癌隐匿性淋巴结转移.

    Release date:2016-08-30 06:32 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content